Vivici develops functional dairy protein ingredients through precision fermentation, marketing them under its Vivitein™ platform. Its first commercial ingredient is Vivitein™ BLG (beta-lactoglobulin), and it has launched Vivitein™ LF (lactoferrin) in the U.S. with self-affirmed GRAS status. The company says customer demand for its ingredients is strong and that the recent funding will allow it to scale supply and market access. Founded in 2023, Vivici plans to use new capital to accelerate innovation and commercialization of its precision-fermented proteins. No revenue or user metrics were disclosed in the articles.

Total raised

$52M

Funding rounds

3

Latest round

Equity

Latest activity

Jun 2026